CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...
Cancer
GSK plc Expands Pipeline with Rgenta Therapeutics Partnership for RNA-Targeted Splice Modulators
GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through...
Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...
Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...
CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...
Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead
Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...
Zhida Pharma Secures Licensing Deal for Vivesto AB’s Apealea in China
Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing...
Guangzhou Virotech’s Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA
Guangzhou Virotech Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has announced receiving tacit clinical approval...
Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from...
Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Shanghai Henlius Biotech’s Serplulimab Approved for First-Line nsNSCLC Treatment in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced that it has received marketing approval from...
HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Jiangsu Hengrui Pharmaceuticals’ Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...
NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment
China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...
Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...